SLDBSolid Biosciences Inc.
$6.82+23% 1Y
$6.82
$3.9352 weeks$11.15
Price
+23%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 3% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for SLDB today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$670.9M
1 year+23%
5 years-81%
Charts
As reported to the SEC, without any scoring.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026On August 6, 2026, Solid Biosciences Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) under the Company’s universal shelf registration statement on Form S-3 (File No. 333-287325) that was originally filed with the Securities and Exchange Commission (the “SEC”) on May 15, 2025 and was …Other event · Form 8-K
- Apr 10, 2026For the sole purpose of achieving an equal balance of membership among the three classes of the Board of Directors (the “Board”) of Solid Biosciences Inc. (the “Company”), effective at 4:00 p.m., Eastern Time, on April 10, 2026, Ilan Ganot, a member of the Board who was serving in Class III (which class will be up for …Director or officer change · Form 8-K
- Mar 12, 2026SGT-003 Interim Clinical Update for INSPIRE DUCHENNE On March 11, 2026, the Company announced positive new interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, a Phase 1/2 first-in-human, open-label, single-dose, multicenter trial designed to evaluate the safety, tolerability and efficacy of SGT-003 in …Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.